Free Trial

MacroGenics (NASDAQ:MGNX) Shares Pass Below 200-Day Moving Average - What's Next?

MacroGenics logo with Medical background

MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.27 and traded as low as $1.37. MacroGenics shares last traded at $1.37, with a volume of 849,316 shares trading hands.

Wall Street Analysts Forecast Growth

MGNX has been the subject of several research analyst reports. Barclays reaffirmed an "overweight" rating and issued a $3.00 price objective (down from $8.00) on shares of MacroGenics in a research note on Wednesday, May 14th. B. Riley dropped their price target on MacroGenics from $5.00 to $3.00 and set a "neutral" rating for the company in a research report on Tuesday, May 20th. HC Wainwright dropped their price target on MacroGenics from $4.00 to $2.00 and set a "neutral" rating for the company in a research report on Tuesday, March 25th. Wall Street Zen raised MacroGenics from a "sell" rating to a "hold" rating in a research report on Saturday, June 7th. Finally, Stifel Nicolaus dropped their price target on MacroGenics from $6.00 to $5.00 and set a "hold" rating for the company in a research report on Wednesday, May 14th. Eight analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $5.71.

View Our Latest Research Report on MGNX

MacroGenics Price Performance

The firm has a market cap of $82.65 million, a PE ratio of -1.47 and a beta of 1.65. The stock has a 50-day moving average price of $1.52 and a 200 day moving average price of $2.22.

MacroGenics (NASDAQ:MGNX - Get Free Report) last issued its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.04). MacroGenics had a negative net margin of 36.23% and a negative return on equity of 59.84%. The firm had revenue of $13.19 million during the quarter, compared to analyst estimates of $9.59 million. As a group, equities research analysts anticipate that MacroGenics, Inc. will post -1.06 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MGNX. Acadian Asset Management LLC boosted its holdings in MacroGenics by 78.8% in the first quarter. Acadian Asset Management LLC now owns 2,308,649 shares of the biopharmaceutical company's stock valued at $2,923,000 after acquiring an additional 1,017,726 shares during the last quarter. Wasatch Advisors LP boosted its holdings in MacroGenics by 37.6% in the fourth quarter. Wasatch Advisors LP now owns 3,488,493 shares of the biopharmaceutical company's stock valued at $11,338,000 after acquiring an additional 952,691 shares during the last quarter. Schonfeld Strategic Advisors LLC acquired a new position in shares of MacroGenics during the fourth quarter worth about $2,787,000. JPMorgan Chase & Co. lifted its stake in shares of MacroGenics by 68.3% during the fourth quarter. JPMorgan Chase & Co. now owns 546,807 shares of the biopharmaceutical company's stock worth $1,777,000 after purchasing an additional 221,905 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in shares of MacroGenics by 69.1% during the fourth quarter. Renaissance Technologies LLC now owns 538,523 shares of the biopharmaceutical company's stock worth $1,750,000 after purchasing an additional 220,100 shares in the last quarter. Institutional investors and hedge funds own 96.89% of the company's stock.

About MacroGenics

(Get Free Report)

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.

Recommended Stories

Should You Invest $1,000 in MacroGenics Right Now?

Before you consider MacroGenics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MacroGenics wasn't on the list.

While MacroGenics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Hot Growth Stocks to Watch Right Now!
Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines